SSX2-4 expression in early-stage non-small cell lung cancer

Tissue Antigens

Volumn 83, Issue 5, 2014, Pages 344-349

  Greve, K B V ^a   Pohl M ^a,b   Olsen, K E ^a,b   Nielsen, O ^b   Ditzel, H J ^a,b   Gjerstorff, M F ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Cancer testis antigen; Immunotherapy; Lung cancer; SSX

Indexed keywords

REPRESSOR PROTEIN; SYNOVIAL SARCOMA X BREAKPOINT PROTEINS; TUMOR PROTEIN;

ALTERNATIVE RNA SPLICING; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; EARLY DIAGNOSIS; GENE EXPRESSION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG; LUNG NEOPLASMS; MALE; METABOLISM; PATHOLOGY; TESTIS;

ALTERNATIVE SPLICING; CARCINOMA, NON-SMALL-CELL LUNG; EARLY DIAGNOSIS; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG; LUNG NEOPLASMS; MALE; NEOPLASM PROTEINS; NEOPLASM STAGING; REPRESSOR PROTEINS; TESTIS;

EID: 84898806657     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/tan.12340     Document Type: Article

References (32)

1. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008: 83: 584-94.
2. Gjerstorff MF, Burns J, Ditzel HJ. Cancer-germline antigen vaccines and epigenetic enhancers: future strategies for cancer treatment. Expert Opin Biol Ther 2010: 10: 1061-75.
3. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005: 5: 615-25.
4. Gure AO, Chua R, Williamson B et al. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res 2005: 11: 8055-62.
5. Sienel W, Varwerk C, Linder A et al. Melanoma associated antigen (MAGE)-A3 expression in Stages I and II non-small cell lung cancer: results of a multi-center study. Eur J Cardiothorac Surg 2004: 25: 131-4.
6. Tyagi P, Mirakhur B. MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy. Clin Lung Cancer 2009: 10: 371-4.
7. Gure AO, Wei IJ, Old LJ, Chen YT. The SSX gene family: characterization of 9 complete genes. Int J Cancer 2002: 101: 448-53.
8. Smith HA, McNeel DG. The SSX family of cancer-testis antigens as target proteins for tumor therapy. Clin Dev Immunol 2010: 150591.
9. Naka N, Joyama S, Tsukamoto Y et al. Quantification of SSX mRNA expression in human bone and soft tissue tumors using nucleic acid sequence-based amplification. J Mol Diagn 2005: 7: 187-97.
10. Taylor BJ, Reiman T, Pittman JA et al. SSX cancer testis antigens are expressed in most multiple myeloma patients: co-expression of SSX1, 2, 4, and 5 correlates with adverse prognosis and high frequencies of SSX-positive PCs. J Immunother 2005: 28: 564-75.
11. Dubovsky JA, McNeel DG. Inducible expression of a prostate cancer-testis antigen, SSX-2, following treatment with a DNA methylation inhibitor. Prostate 2007: 67: 1781-90.
12. Smith HA, McNeel DG. The SSX family of cancer-testis antigens as target proteins for tumor therapy. Clin Dev Immunol 2010: 2010: 150591.
13. Valmori D, Qian F, Ayyoub M et al. Expression of synovial sarcoma X (SSX) antigens in epithelial ovarian cancer and identification of SSX-4 epitopes recognized by CD4+ T cells. Clin Cancer Res 2006: 12: 398-404.
14. Fradet Y, Picard V, Bergeron A, LaRue H. Cancer-testis antigen expression in bladder cancer. Prog Urol 2006: 16: 421-8.
15. Tureci O, Chen YT, Sahin U et al. Expression of SSX genes in human tumors. Int J Cancer 1998: 77: 19-23.
16. Tajima K, Obata Y, Tamaki H et al. Expression of cancer/testis (CT) antigens in lung cancer. Lung Cancer 2003: 42: 23-33.
17. dos Santos NR, Torensma R, de Vries TJ et al. Heterogeneous expression of the SSX cancer/testis antigens in human melanoma lesions and cell lines. Cancer Res 2000: 60: 1654-62.
18. Smith HA, Cronk RJ, Lang JM, McNeel DG. Expression and immunotherapeutic targeting of the SSX family of cancer-testis antigens in prostate cancer. Cancer Res 2011: 71: 6785-95.
19. Liang J, Ding T, Guo ZW et al. Expression pattern of tumour-associated antigens in hepatocellular carcinoma: association with immune infiltration and disease progression. Br J Cancer 2013: 109: 1031-9.
20. Akcakanat A, Kanda T, Tanabe T et al. Heterogeneous expression of GAGE, NY-ESO-1, MAGE-A and SSX proteins in esophageal cancer: Implications for immunotherapy. Int J Cancer 2006: 118: 123-8.
21. Inagaki H, Nagasaka T, Otsuka T, Sugiura E, Nakashima N, Eimoto T. Association of SYT-SSX fusion types with proliferative activity and prognosis in synovial sarcoma. Mod Pathol 2000: 13: 482-8.
22. dos Santos NR, de Bruijn DR, Kater-Baats E, Otte AP, van Kessel AG. Delineation of the protein domains responsible for SYT, SSX, and SYT-SSX nuclear localization. Exp Cell Res 2000: 256: 192-202.
23. Tureci O, Sahin U, Schobert I et al. The SSX-2 gene, which is involved in the t(X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40. Cancer Res 1996: 56: 4766-72.
24. Serrano A, Lethe B, Delroisse JM et al. Quantitative evaluation of the expression of MAGE genes in tumors by limiting dilution of cDNA libraries. Int J Cancer 1999: 83: 664-9.
25. Lethe B, van der Bruggen P, Brasseur F, Boon T. MAGE-1 expression threshold for the lysis of melanoma cell lines by a specific cytotoxic T lymphocyte. Melanoma Res 1997: 7 (Suppl 2): S83-8.
26. Gjerstorff M, Pohl M, Olsen K, Ditzel H. Analysis of GAGE, NY-ESO-1 and SP17 cancer/testis antigen expression in early stage non-small cell lung carcinoma. BMC Cancer 2013: 13: 466.
27. Dacic S. Molecular genetic testing for lung adenocarcinomas: a practical approach to clinically relevant mutations and translocations. J Clin Pathol 2013: 66: 870-4.
28. Sigalotti L, Coral S, Altomonte M et al. Cancer testis antigens expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implications. Br J Cancer 2002: 86: 979-82.
29. Daskalakis M, Nguyen TT, Nguyen C et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment. Blood 2002: 100: 2957-64.
30. Esteller M. DNA methylation and cancer therapy: new developments and expectations. Curr Opin Oncol 2005: 17: 55-60.
31. Bussolati G, Leonardo E. Technical pitfalls potentially affecting diagnoses in immunohistochemistry. J Clin Pathol 2008: 61: 1184-92.
32. Ramos-Vara JA. Technical aspects of immunohistochemistry. Vet Pathol 2005: 42: 405-26.